More generic competition for Sanofi's Eloxatin in Europe as Strides gets UK nod
This article was originally published in Scrip
Executive Summary
Even as Sanofi-Aventis continues to rake in US sales of its colon cancer drug Eloxatin (oxaliplatin injection) through a court order keeping generic versions off the market there, more firms are set to launch into Europe.